A5061443644- Systemic Lupus Erythematosus Research
- Platelet Disorders and Treatments
- Systemic Sclerosis and Related Diseases
- Rheumatoid Arthritis Research and Therapies
- Pulmonary Hypertension Research and Treatments
- Atherosclerosis and Cardiovascular Diseases
- Monoclonal and Polyclonal Antibodies Research
- Diabetes and associated disorders
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Renal Diseases and Glomerulopathies
- Autoimmune and Inflammatory Disorders Research
- Cell Adhesion Molecules Research
- Complement system in diseases
- Blood disorders and treatments
- Phagocytosis and Immune Regulation
- Reproductive System and Pregnancy
- Blood Coagulation and Thrombosis Mechanisms
- Pregnancy and Medication Impact
- Liver Diseases and Immunity
- Bone health and treatments
- T-cell and B-cell Immunology
- Peripheral Neuropathies and Disorders
- Inflammatory Myopathies and Dermatomyositis
- Lymphoma Diagnosis and Treatment
- Heparin-Induced Thrombocytopenia and Thrombosis
Kitasato University
2021-2024
Johns Hopkins University
2023
Methodist Hospital
2023
Hokkaido University
2013-2022
Baylor University Medical Center
2021
Imperial College London
2021
Center for Rheumatology
2015
Health Sciences University of Hokkaido
2010
Hayashibara (Japan)
2006
Nara Institute of Science and Technology
2006
Objectives. Haemophagocytic syndrome (HPS) is known as a relatively rare complication in autoimmune diseases. Here we analysed the clinical features of HPS patients with systemic Methods. One thousand and fourteen diseases admitted to Hokkaido University Hospital from 1997 2007 were recruited [350 SLE, 136 RA, 98 polymyositis/dermatomyositis (PM/DM), 88 SSc, 91 vasculitis syndrome, 37 primary SS, 26 adult onset Still's disease (AOSD) 188 other diseases]. Clinical treatment outcomes...
Abstract Objective To define the antiphospholipid score (aPL‐S) by testing multiple antibodies (aPL) and to evaluate its efficacy for diagnosis of syndrome (APS) predictive value thrombosis. Methods This study comprised 2 independent sets patients with autoimmune diseases. In first set (n = 233), aPL profiles were analyzed. Five clotting assays lupus anticoagulant 6 enzyme‐linked immunosorbent (IgG/IgM anticardiolipin antibodies, IgG/IgM anti–β ‐glycoprotein I, phosphatidylserine‐dependent...
To investigate the significance of complement activation in patients with primary antiphospholipid syndrome (APS).Thirty-six APS, 42 control non-systemic lupus erythematosus (SLE) connective tissue diseases, and 36 healthy volunteers were analysed retrospectively. Serum levels (C3, C4, CH(50)) anaphylatoxins (C3a, C4a, C5a) examined all subjects, serum regulatory factors (factor H factor I) measured APS. Plasma anticoagulant activity was determined a mixing test using activated partial...
Objective. Interstitial lung diseases (ILDs) complicated with PM or DM are frequently aggressive and refractory to treatment. Recently some reports have suggested the potential benefit of tacrolimus for severe ILD PM/DM. However, little evidence has yet shown efficacy in these settings. The aim this study was evaluate as a treatment PM-/DM-related ILD. Methods. This retrospective comprised 49 previously untreated patients diagnosed admitted Hokkaido University Hospital from January 2000 July...
The purpose of this study is to propose Context-Aware Support Vector Machine (C-SVM) for application in a context-dependent recommendation system. It important consider users' contexts information as preference change with context. However, currently there are few methods which take into account (e.g. time, place, the situation and so on). Thus, we extend functionality Machines (SVM), popular classifier method used between two classes, by adding axes context feature space order We then...
Objective A task force of scientists at the International Congress on Antiphospholipid Antibodies recognized that phosphatidylserine-dependent antiprothrombin antibodies (aPS/PT) might contribute to a better identification antiphospholipid syndrome (APS). Accordingly, initial and replication retrospective, cross-sectional multicentre studies were conducted ascertain value aPS/PT for APS diagnosis. Methods In study (eight centres, seven countries), clinical/laboratory data retrospectively...
To assess the value of a combination anti-β2 -glycoprotein I (anti-β2 GPI) domain antibody and anti-phosphatidylserine/prothrombin complex (anti-PS/PT) tests for diagnosis antiphospholipid syndrome (APS).This cross-sectional study involved cohort patients who visited our clinic from April 2005 to March 2013. Tests GPI antibodies, IgG anti-PS/PT IgM together with criteria-defined antibodies (aPL), were performed in all patients. The total score (aPL-S) was calculated each patient according...
Objective: To study the clinical and immunological manifestations of antiphospholipid syndrome (APS) in Japanese population by a single-centre registration. Methods: In this retrospective cohort study, 141 consecutive patients with APS, fulfilling Sydney revised Sapporo criteria for definite who visited our autoimmune clinic from 1988 to 2010, were recruited followed up. All interviewed underwent general physical examination qualified rheumatologists on day blood sampling. Results: The...
We aimed to investigate the involvement of macroautophagy/autophagy in autoimmunity rheumatoid arthritis (RA) through citrullination VIM (vimentin) and its interaction with MHC class II synovial fibroblasts (SFs). The cell surface expression B7 costimulatory molecules on SFs was analyzed by flow cytometry after treatment IFNG/IFN-γ (interferon gamma). Intracellular citrullinated autoantigens were immunoblotting using serum from anti-citrullinated peptide antibodies (ACPA)-positive patient as...
The objective of this study is to identify the effects statins and risk factors for thrombosis in patients with new onset systemic lupus erythematosus (SLE) or without antiphospholipid antibodies (aPL). Consecutive SLE history thrombotic events were retrospectively enrolled from April 1997 February 2014. development first death caused by defined as endpoint. Risk protective developing analyzed. A total 152 patients, 80 positive 72 negative aPL, included. In aPL-positive 15 developed arterial...
Warfarin is regarded as the standard treatment for preventing thrombotic events in APS, but recurrence rate still high. Dual antiplatelet therapy (DAPT) has been shown to be effective prevention of acute coronary syndrome or stroke. The objective this study was evaluate efficacy DAPT thrombosis APS patients with history arterial thrombosis.This retrospective cohort conducted at Hokkaido University Hospital between 1990 and 2016. secondary prophylactic effects safety warfarin monotherapy...
Idiopathic osteonecrosis of the femoral head (ION) is a common complication SLE associated with CS therapy. Although pathogenesis ION involves local bone ischaemia favoured by thrombophilia, involvement aPL in lupus remains to be elucidated. We have previously reported score (aPL-S) as quantitative marker and development thrombotic events autoimmune diseases. The aim this study was identify impact on using aPL-S.This single-centre retrospective comprising 88 consecutive patients who...
Objective: To describe the pre-conception status, pregnancy outcomes, and medication prevalence in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Crohn's disease (CD), ulcerative colitis (UC).Methods: E-mail-based questionnaire survey for Japan Maternal Fetal Intensive Care Unit Network hospitals inquiring clinical features of SLE, RA, CD UC complicated pregnancies 2 years.Results: The number among 69,810 deliveries was 184, 139, 27 178, respectively. Less than half were...
Abstract Objective Using cluster analysis, to identify the subgroup of patients with APS poorest prognosis and clarify characteristics that subgroup. Methods This is a longitudinal retrospective cohort study patients. clinical data profile aPL, analysis was performed classify into subgroups. Events were defined as thrombosis, severe bleeding, mortality. Results A total 168 included. Cluster classified three subgroups; (n = 61): secondary APS, B 56): accumulation cardiovascular risks arterial...